Related Experiment Videos
APOA1 polymorphism influences risk for early-onset nonfamiliar AD
Heike Vollbach1, Reinhard Heun, Chris M Morris
1Department of Psychiatry, University of Bonn, Bonn, Germany.
Annals of Neurology
|September 1, 2005
Summary
Genetic variations in apolipoprotein A1 (APOA1) may influence Alzheimer's disease (AD) risk. Specifically, the APOA1 -75bp G/A polymorphism’s A allele is linked to earlier onset and increased risk for AD in younger individuals.
Area of Science:
- Neuroscience
- Genetics
- Metabolic Disorders
Background:
- Cholesterol homeostasis plays a role in Alzheimer's disease (AD) risk.
- Apolipoprotein A1 (APOA1), a key component of high-density lipoprotein, is crucial for cholesterol transport.
- APOA1 gene variations may affect brain cholesterol metabolism and AD susceptibility.
Purpose of the Study:
- To investigate the association between APOA1 promoter polymorphisms and Alzheimer's disease risk.
- To determine if specific APOA1 gene variants influence the age of onset for AD.
Main Methods:
- Case-control study involving 427 AD patients and 500 healthy controls.
- Genotyping of two APOA1 promoter polymorphisms: -75bp G/A and +83/84bp C/T or G/A.
- Statistical analysis to compare allele frequencies and their correlation with AD risk and age at onset.
Main Results:
- The A allele of the APOA1 -75bp G/A polymorphism was associated with an increased risk of AD in individuals aged 66 years or younger.
- AD patients homozygous for the A allele at -75bp experienced disease onset approximately 8 years earlier than those with at least one G allele.
- The APOA1 +83/84bp polymorphism showed no significant influence on AD risk.
Conclusions:
- APOA1 gene variants, particularly the -75bp G/A polymorphism, may impact Alzheimer's disease risk and age of onset.
- These findings highlight the potential role of cholesterol metabolism-related genes in AD pathogenesis.
- Further research is warranted to elucidate the precise mechanisms linking APOA1 variants to AD.